Core Concepts
Antidrug antibodies impact RA biologic drug response.
Abstract
In a prospective cohort study, researchers analyzed data from 230 RA patients initiating treatment with various biologic drugs. Antidrug antibody positivity was associated with diminished response to treatment, particularly anti-TNF mAbs. Monitoring antidrug antibodies may aid in managing nonresponsive RA patients. The study was reported by Samuel Bitouin, MD, PhD, in JAMA Network Open on July 12, 2023, funded by the European Union Innovative Medicines Initiative. Limitations include the study not being powered to show associations for each drug class.
Stats
Antidrug antibody positivity at month 12: 38.2% for anti-TNF mAbs, 6.1% for etanercept, 50.0% for rituximab, and 20.0% for tocilizumab.
Odds ratio for EULAR response at month 12: 0.19 (95% CI, 0.09-0.38; P < .001).
Mean difference in drug concentration of anti-TNF mAbs between antidrug antibody–negative vs positive patients: -9.6 mg/L (95% CI, -12.4 to -6.9; P < .001).
Quotes
"Findings suggest that antidrug antibodies are associated with nonresponse to biologic drugs."
"Antidrug antibodies, BMI, and rheumatoid factor inversely associated with treatment response."